Endo International (NASDAQ: ENDP) and RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.
Valuation & Earnings
This table compares Endo International and RegeneRx Biopharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Endo International||$4.01 billion||0.41||-$3.35 billion||($22.45)||-0.33|
Volatility & Risk
Endo International has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, RegeneRx Biopharmaceuticals has a beta of -2.78, suggesting that its share price is 378% less volatile than the S&P 500.
This is a breakdown of recent recommendations for Endo International and RegeneRx Biopharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Endo International currently has a consensus price target of $11.81, suggesting a potential upside of 58.77%. RegeneRx Biopharmaceuticals has a consensus price target of $1.50, suggesting a potential upside of 552.46%. Given RegeneRx Biopharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe RegeneRx Biopharmaceuticals is more favorable than Endo International.
Insider & Institutional Ownership
93.2% of Endo International shares are owned by institutional investors. Comparatively, 0.2% of RegeneRx Biopharmaceuticals shares are owned by institutional investors. 0.5% of Endo International shares are owned by insiders. Comparatively, 12.1% of RegeneRx Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares Endo International and RegeneRx Biopharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Endo International beats RegeneRx Biopharmaceuticals on 7 of the 13 factors compared between the two stocks.
About Endo International
Endo International PLC, formerly Endo Health Solutions Inc. is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel. The Company operates in three segments: Endo Pharmaceuticals, Qualitest and AMS. In June 2014, the Company’s subsidiary, Endo Pharmaceuticals sold its pharmaceutical drug discovery platform to AsanaBioSciences, LLC. In June 2014, Asana BioSciences, LLC, an independent member of Amneal Alliance of Companies, acquired early-stage branded pharmaceutical discovery platform of Endo Pharmaceuticals, a subsidiary of Endo International plc. In June 2014, Trendlines Group acquired intellectual property developed within the framework of an R&D agreement with the Company. In July 2014, it acquired Grupo Farmaceutico Somar.
About RegeneRx Biopharmaceuticals
RegeneRx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company’s segment is the development and marketing of product candidates based on Tb4, an amino acid peptide. The Company has formulated Tb4 into three product candidates in clinical development: RGN-259, RGN-352 and RGN-137. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptide that is originally isolated from bovine thymus glands. RGN-259 is its preservative-free eye drop formulation of Tb4. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration. RGN-137 is a topical gel for dermal wounds and reduction of scar tissue.
What are top analysts saying about Endo International PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Endo International PLC and related companies.